All In Biotech

Drug Trial Radar · NCT00409175

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study

Last checked: Nov 20, 2026Latest source record: Dec 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Jan 2007

Primary completion

May 2009

Study completion May 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP). Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP. The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience. This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.

Conditions

  • Familial Amyloid Polyneuropathy

Interventions

  • Fx-1006ADrug

    Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

  • PlaceboDrug

    Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18Time frame: Month 18
  2. Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18Time frame: Baseline, Month 18

Locations

10 sites in 9 countries. Site status is shown where the registry gives one.

  • MGH Neuropathy Laboratory

    Boston, Massachusetts

  • FLENI-Hepatology and Organ Transplant Dept.

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • Hospital Universitário Prof. Clementino Fraga Filho-UFRJ

    Rio de Janeiro, Southeast, Brazil

  • CHU de Bicetre

    Le Kremlin-Bicêtre, Île-de-France Region, France

  • Universitatsklinikum Munster, Transplant Hepatology

    Münster, North Rhine-Westphalia, Germany

  • Serviço de Neurologia-Hospital de Santa Maria

    Lisbon, Lisbon District, Portugal

  • Unidade Clinica de Paramiloidose-Hospital Santo Antonio

    Porto, Norte, Portugal

  • Hospital Clinic de Barcelona

    Barcelona, Catalonia, Spain

  • Umea University Hospital

    Umeå, Västerbotten County, Sweden

  • Kings College Hospital

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.